Home / Beef Cattle / Vaccines / Rispoval IBR-Marker inactivated
1. IBR abortion protection
Only Rispoval IBR vaccines provide IBR abortion protection. To prevent IBR abortions use:
-
A single intramuscular dose of Rispoval IBR-Marker live followed 6 months later by
a single dose booster using Rispoval IBR-Marker inactivated -
Two intramuscular doses of Rispoval IBR-Marker live 3-5 weeks apart
Thereafter, single dose booster vaccinations should be administered
-
Every 12 months (if using Rispoval IBR-Marker inactivated)
-
Every 6 months (if using Rispoval IBR-Marker live)
No other IBR vaccines are licensed for IBR abortion protection.
2. Annual IBR booster
A single dose of Rispoval IBR Marker live requires a single dose booster vaccination 6 months later with either:
-
Rispoval IBR-Marker live to provide 6 months of protection
-
Rispoval IBR-Marker inactivated to provide 12 months of protection
Thereafter, single dose booster vaccinations should be administered:
-
Every 6 months (if using Rispoval IBR-Marker live) or
-
Every 12 months (if using Rispoval IBR-Marker inactivated)
3. Animals at immediate risk of IBR
Rispoval IBR-Marker live is used as a single dose intramuscular injection in cattle over 3 months of age, to provide 6 months duration of immunity. Cattle at immediate risk, e.g. in the face of an outbreak, should receive a single dose of Rispoval IBR-Marker live intranasally, followed by a single dose of Rispoval IBR-Marker live intramuscularly 3-5 weeks later.
No other IBR vaccines are licensed for use in cattle at immediate risk of IBR.
Rispoval IBR-Marker inactivated is an inactivated (dead) IBR vaccine from Zoetis. This vaccine can be used in conjunction with Rispoval IBR-Marker live to provide 12 months duration of immunity.
There are a number of different vaccination programme options when using Rispoval IBR Vaccines. (see below for further details). In summary, both Rispoval IBR-live and Rispoval IBR-inactivated provide 6 months protection against IBR, but when the two vaccines are used in combination, it is possible to vaccinate every 12 months; i.e. use Rispoval IBR-Marker live (6 months protection) followed by Rispoval IBR-Marker inactivated (12 months protection) and use Rispoval IBR-Marker inactivated every 12 months thereafter.
Rispoval IBR Options (for animals over 3 months of age*)
Rispoval IBR-Marker inactivated (subcutaneously)
Primary course: 2 doses 3-5 weeks apart
Booster: 1 dose every 6 months
Rispoval IBR-Marker live (intramuscularly)
Primary course: 1 dose
Booster: 1 dose every 6 months
Rispoval IBR 12 month vaccination programme
Primary course: 1 dose Rispoval IBR-Marker live (intramuscularly)
6 month Booster: 1 dose Rispoval IBR-Marker inactivated (subcutaneously)
Annual booster: 1 dose Rispoval IBR-Marker inactivated (subcutaneously)
Product Information:
Suspension for injection
Presentations: 10 dose (20ml) and 50 dose (100ml)
Active Ingredient: Bovine Herpes Virus type 1 (BHV-1) strain Difivac (gE negative)
Indications: For active immunisation of cattle against Infectious Bovine Rhinotracheitis (IBR), to reduce the clinical signs and virus shedding and, in female cattle, to prevent abortions associated with BHV-1 infection
Dosage: 2ml by subcutaneous injection. Please see data sheet for vaccination scheme
Withdrawal: 0 days
Legal Category: POM (E)
VPA Number: 10438/086/001
Summary of Product Characteristics: Full product licence here
- Argentina
- Australia
- Austria
- Belgium
- Bolivia
- Brazil
- Bulgaria
- Canada
- Chile
- China
- Colombia
- Costa Rica
- Croatia
- Czech Republic
- Denmark
- Ecuador
- Egypt
- Estonia
- Ethiopia
- Finland
- France
- Germany
- Ghana
- Greece
- Hungary
- India
- Indonesia
- Ireland
- Israel
- Italy
- Japan
- Kenya
- Latvia
- Liberia
- Lithuania
- Malawi
- Malaysia
- Mauritius
- Mexico
- Morocco
- Mozambique
- Netherlands
- New Zealand
- Nigeria
- Paraguay
- Peru
- Philippines
- Poland
- Portugal
- Romania
- Russia
- Serbia
- Singapore
- Slovakia
- Slovenia
- South Africa
- South Korea
- Spain
- Switzerland
- Taiwan
- Tanzania
- Thailand
- Turkey
- Uganda
- Ukraine
- United Kingdom
- United States
- Uruguay
- Vietnam
- Zambia
- Zimbabwe
You are now leaving the regional website to access another site in the group.
Regulatory constraints and medical practices vary across regions from market to market. Consequently, the information provided on the site in which you enter may not be suitable for use in your region.